Grade: Pharmaceutical Grade

Factory Location: QUANZHOU

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Ribociclib is a treatment for advanced breast cancer developed by Novartis Pharmaceuticals. 

Indication: HR-positive, HER2-negative Andvance ormetastaticbreast Cancers

All the products under the patent are only for R&D use.

Patent from Novartis Pharmaceuticals, expiry date(The U.S):Jun.27,2028.